Calamos Advisors
NVO

Calamos Advisors’s Novo Nordisk NVO Stock Holding History

Calamos Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-64,800
Closed -$4.47M – 982
2025
Q3 		$4.47M Buy
+64,800
New +$3.79M 0.02% 552
2025
Q2 		– Sell
-95,100
Closed -$8.18M – 969
2025
Q1 		$8.18M Buy
+95,100
New +$7.85M 0.04% 435

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Calamos Advisors's NVO Position: Q2 2026 in Review

Calamos Advisors held its Novo Nordisk (NVO) position steady in Q2 2026 at 98,472 shares worth $4.72M. The position accounts for 0.02% of the portfolio, ranked #553.

Calamos Advisors first reported a position in NVO in Q2 2013 and has held it in 31 quarters since. The position peaked at $43.4M in Q2 2024. 1,356 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Calamos Advisors held 98,472 shares of Novo Nordisk worth $4.72M as of Q2 2026.
  • Calamos Advisors left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.02% of Calamos Advisors's portfolio in Q2 2026, its #553 holding.
  • Calamos Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 31 quarters since.
  • Calamos Advisors's Novo Nordisk position peaked at $43.4M in Q2 2024.
  • 1,356 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.